Возможности применения IF-ингибиторов в клинической практике

1. Hjalmarson A, Gilpin EA, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547–53.
2. Jouven X, Empana J-P, Schwartz P. Heart Rate Profile during Exercise e as a Predictor of Sudden Cardiac Death. N Eng J Med 2005; 352: 1951–8.
3. Kannel WB, Kannel C, Paffangarger RSJr et al. Heart rate and cardiovascular mortality: the Framingem study. An Heart J 1987; 113: 1489–94.
4. Kristal-Boneh E, Silber H, Harari G et al. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up 0f 3257 male Israel employees. Eur Heart Journal 2000; 21: 115–24.
5. Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология. 2005; 10: 45–50.
6. Gilman M, Kannel W, Belanger A, D'Agostino R. Influence of heart rate on mortality among persons with hypertension The Framingham study. Am Heart J 1993; 125: 1148–54.
7. Gillum R, Makus D, Feldman J. Pulse rate, coronary heart disease and death: The NHANES I epidemiological follow-up study. Am Heart J 1991; 121: 172–7.
8. Shell W, Sobel B. Deleterious effects of increased heart rate on infarct size in the conscious dog. Am J Cardiol 1973; 31: 474–9.
9. Perski A, Hamsten A, Lindvall K, Theorel T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J 1988; 116: 1369–73.
10. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1241–381.
11. Tardif JC, Ford I, Tendera M et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529–36.
12. Borer J, Fox K, Jaillon P. Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina. A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial. Circulation 2003; 107: 817–23.
13. Ruzyllo W, Ford I, Tendera M, Fox K. Antianginal and antischemic effects of the If current inhibitor Ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. Randomised, controlled, double-blind trial. 2004; 25 (Suppl.): 878; p. 138.
14. Moosmang S, Stieber J, Zong X et al. Cellular expression and functional characterization of four hyperpolarization-activated pacemaker channels in cardiac and neuronal tissues. Eur J Biochem 2001; 268: 1646–52.
15. CIBIS II Investigators and committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet 1999; 353: 9–13.
16. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353 (9169): 2001–7.
17. Packer M, Coats, AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344 (22): 1651–8.
18. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008; 372: 817–21.
19. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–16.
20. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected pr proven coronary heart disease. Eur Heart J 2005; 26 (10): 967–74.
21. Bucchi A, Tognati A, Milanesi R et al. Properties of ivabradine-induced block of HCN1 and HCN4 channels. J Physiol 2006; 572 (2): 335–46.
22. Low PA et al. Postural tachycardia syndrome (POTS). Neurology 1985; 45 (Suppl. 5): S19–S25.
23. Morillo CA, Klein GJ, Thakur RK et al. Mechanism of "inappropriate" sinus tachycardia: the role of sympathovagal balance. Circulation 1994; 90: 873–7.
24. Yusuf Sh, Camm J. Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? Review. J Cardiovasc Pharmacol Ther 2003; 8 (2): 89–105.
25. Yusuf Sh, Camm J. The sinus tachycardias. Nat Clin Pract Cardiovasc Med 2005; 2 (1): 44–52. Review.
26. Goldstein R, Ozanne G, Schmellin W. VAPOOR analytic Database Combining Physiologic and Electronic Medical Record Data Facilites Knowledge discovery and Outcomes Research. Anestesiology 200; 99: A418.
27. ACC/AHA Guideline update for perioperative cardiovascular evaluation for noncardiac surgery – executive summary. Circulation 2002; 105: 1257–67.
28. Poldermans D, Boersma E, Baxx JJ et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiograpgy Study Group. N Engl J Med 1999; 341: 1789–94.
29. Mangano DT, Laryug EL, Wallace A, Tateo I. Effect of atenolol on mortality after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713–20.
30. Hoppe UC, Jansen E, Sudkampf M et al. A hyperpolarisation-activated inward current (If) in ventricular myocytes from normal and failing human hearts. Circulation 1998; 97: 55–65.

Н.Ш.Загидуллин, Ш.З.Загидуллин, Е.О.Травникова, Р.Х.Зулькарнеев